Chugai and Renalys Pharma, Inc. announced positive topline results from its Phase III clinical study of sparsentan (RE 021), an orally administered dual endothelin and angiotensin II receptor… read more.
A new paper in Rheumatology Advances in Practice, published by Oxford University Press, indicates that Tik Tok videos about gout are commonly misleading, inconsistent, or inaccurate. Gout is a painful… read more.
A new major study from Queen Mary University of London has found that smokers who use both cigarettes and e-cigarettes at the same time – known as dual… read more.
GSK plc announced that the FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adult and paediatric patients… read more.
At any one time, nearly 1 in 5 emergency department patients in the UK is being cared for in corridors, waiting rooms, and other non-standard ‘overflow’ spaces—an approach… read more.
A landmark UK study has revealed that acute heavy menstrual bleeding (HMB) is placing a significant hidden burden on the NHS, with around £13 million spent annually on… read more.
Abivax SA a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases,… read more.
The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in adult and adolescent patients 12 years and above with inadequate response… read more.
A test using genetics to predict who is at the highest risk of developing type 1 diabetes could one day be applied to largescale health studies, to identify… read more.
A new doctoral dissertation from the University of Vaasa, Finland, argues that healthcare cybersecurity will remain fragile unless technology, humans and organisational processes are treated as a single… read more.
Novo Nordisk announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg, to be used… read more.
Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
